Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.10 +2.47%

+$0.76 today

Market cap
$365.03M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.28M

Average 0.16M

NGNE EBITDA Margin

EBITDA as a percentage of revenue.

Neurogene Inc.NASDAQ: NGNE

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2024
-7771.4%
Year-over-year change
—
Reported Analyst consensus estimate

EBITDA Margin vs competitors

How NGNE compares with its peers on the latest reported figures

NGNE Competitors Peer median
EBITDA Margin for NGNE and competitors
Company Period LTM level YoY 3-year change
MGTXMeiraGTx Holdings plcLTM Mar 2026-120.0% +290.8 pp+619.2 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-185.2% +738962.6 pp+3203.1 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-308.4% -186.1 pp-189.2 pp
ALECAlector, Inc.LTM Mar 2026-632.1% -502.0 pp-541.5 pp
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-2712.3% -1582.7 pp+5281.1 pp
NGNENeurogene Inc.FY2025— ——
DSGNDesign Therapeutics, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding NGNE) -308.4%-186.1 pp+619.2 pp

Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000925K0
Cost of Revenue42.26M3.2M3.26M3.25M3.19M
Gross Profit(42.26M)(3.2M)(3.26M)(2.32M)(3.19M)
Gross Margin———-251.0%—
Research & Development42.26M47.51M44.39M60.92M75.01M
Selling, General & Admin8.27M9.01M11.19M22.61M25.13M
Operating Expenses8.27M53.32M52.32M80.28M100.02M
Depreciation & Amortization947K3.2M3.3M3.25M3.09M
EBITDA(49.57M)(51.99M)(33.01M)(71.89M)(87.25M)
EBITDA Margin———-7771.4%—
Operating Income(50.53M)(56.52M)(55.58M)(82.61M)(103.21M)
Operating Margin———-8930.3%—
Interest Income19K1.34M2.95M8.47M11.55M
Interest Expense02K12K12K5K
Other Income / Expenses17K1.33M19.27M7.46M12.86M
Income Before Tax(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Pre-Tax Margin———-8123.7%—
Income Tax Expense00000
Net Income(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Net Margin———-8123.7%—
EPS (Basic)(0.92)(4.30)(2.83)(4.28)(4.24)
EPS (Diluted)(0.92)(4.30)(2.83)(4.28)(4.24)
Weighted Avg Shares55.04M12.82M12.82M17.57M21.17M
Weighted Avg Shares (Diluted)55.04M12.82M12.82M17.57M21.17M

Neurogene Inc.

NASDAQ:NGNE

Intrinsic Alpha fair value

Locked

Current Price

$23.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.